x
SIGN UP
About Us
Back
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science & Technology
Back
Protein Misfolding
SEE-Tx™ Platform
STARs
Publications
Posters
Pipeline
Back
Investors & Media
Back
Overview
News and Events
Stock Information
SEC Filings
Corporate Governance
Investor Resources
Analyst Coverage
Contact Us
Back
Perspectives
SearchIcon
Newsroom
Search
In the news
Parkinson’s News Today
Gain Therapeutics cleared to start GT-02287 Phase 1 trial in Australia
Precision Medicine Online
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
BioWorld
Gain Therapeutics receives Australian HREC approval to begin phase I study of GT-02287 for GBA1-Parkinson’s disease
Nasdaq
Gain Therapeutics: Tackling Rare Diseases at the Genetic Level
Parkinson’s News Today
Oral therapy GT-02287 shows promise in Parkinson’s mice models
The Authority Magazine
The Future Is Now: Matthias Alder Of Gain Therapeutics On How Their Technological Innovations Will Shake Up The Tech Scene
BioSpace
Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease
Parkinsons News Today
STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s
Neurology Live
A New Approach to Protein Misfolding in Parkinson Disease
Parkinsons News Today
Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s
Benzinga
Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding
Medscape Medical News
Positive Topline Results for Novel Parkinson's Treatment
BioTalk
BioTalk with Rich Bendis
US News
Direct Listing vs. IPO
RareDaily
Gain Therapeutics Raises $40M in IPO to Advance Rare Disease Pipeline
Nasdaq
Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint
pm360
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
Pharmaceutical Technology
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
BioWorld
Gain Therapeutics Inc. signs a collaboration with Sumitomo Dainippon Pharma Co. Ltd.
BioSpace
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
Proactive
Gain Therapeutics finalizing animal proof-of-concept study in Parkinson's Disease
